Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00649584 · ClinicalTrials.gov registry record · Phase 1
A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
A Phase 1 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT00649584 is a Phase 1 study that was terminated before completion, run by Seagen. The registered enrollment target is 44 participants.
The verdict
NCT00649584, a Phase 1 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
This study will examine the safety profile of SGN-35 alone and in combination with gemcitabine. The study will test increasing doses of SGN-35 given weekly to small groups of patients.
Interventions
- DRUG gemcitabine
- DRUG SGN-35
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2008-03 |
| Est. Completion | 2010-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00649584
The ClinicalTrials.gov registry entry for NCT00649584 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which gemcitabine is the first listed.
NCT00649584 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00649584 about?
NCT00649584 is a clinical study titled "A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies". This study will examine the safety profile of SGN-35 alone and in combination with gemcitabine. The study will test increasing doses of SGN-35 given weekly to small groups of patients.
What is the current status of trial NCT00649584?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2008-03. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00649584?
The interventions under investigation include: gemcitabine (DRUG), SGN-35 (DRUG).
Who is sponsoring clinical trial NCT00649584?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.